Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $300 Price Target
Portfolio Pulse from Benzinga Newsdesk
Chardan Capital has reiterated its Buy rating for Alnylam Pharmaceuticals, maintaining a price target of $300.
October 11, 2024 | 6:27 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Chardan Capital has reiterated its Buy rating for Alnylam Pharmaceuticals, maintaining a price target of $300.
The reaffirmation of a Buy rating and a $300 price target by Chardan Capital is a positive signal for investors, suggesting confidence in Alnylam's future performance. This could lead to increased investor interest and potentially a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100